Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 13, 2023 5:14pm
162 Views
Post# 35540204

RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

RE:RE:Inflation Reduction Act (IRA) boosts biological drugs July 11, 2023 - Increasing longevity and the resulting healthcare opportunity are seen as one of four unstoppable trends reshaping the world and transforming the ways we live and work, according to Julie Koo of Citi Global Wealth Investments.

"Over the last few years, technological innovation has disrupted multiple sectors including healthcare. We’re seeing tremendous innovation in industries such as biotech, leading to new treatments to address fatal diseases like cancer. Immune oncology, for example, is helping to treat cancer by tapping into a patient’s immune system to detect and destroy harmful cells. This is a significant improvement over treatment methods such as chemotherapy and radiation.", Koo continued to say.

Ken Takeshita of Daiichi Sankyo says: “Advancements in the understanding of disease at both the molecular and cellular level are among the main reasons why we have seen significant improvement in the treatment of certain diseases, such as cancer and hereditary illnesses.”

"Beyond ADCs, we have collaborated with academic researchers to launch the first oncolytic virus in Japan for patients with malignant glioma. We have also gained extensive experience in the clinical development and manufacturing of a CAR T-cell therapy, through a partnership with a global leader in cell therapy", Takeshita said.

"It takes approximately 10 to 15 years and more than US$2.6 billion on average, to bring a new (small-moleccule) medicine to market, according to the Pharmaceutical Research and Manufacturers of America (PhRMA)." - Takeshita added.

The PhRMA represents the (small molecule) pharmaceutical industry in the United States.


https://www.businesstimes.com.sg/wealth/banking-healthcare-innovation
<< Previous
Bullboard Posts
Next >>